The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
CD&D Patient Decision Aids Resource available at: http://medicines.necsu.nhs.uk/guidelines/durham-darlington/
200mg in 20mL, 500mg in 10mL and 1g in 10mL solution for injection
Use in mental health in ECT suite also considered RED
50% nitrous oxide and 50% oxygen mixture used for analgesia
MHRA Drug Safety Update December 2008: Nitrous oxide: neurological and haematological side-effects
Penthrox(R)
For use in A&E only for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain. Also for patients recieving electrochemotherapy.
MHRA Drug Safety Update December 2008: Nitrous oxide: neurological and haematological side-effects
5mg in 5ml (1mg/ml) injection
10mg in 2ml injections
50mg in 5mL pre-filled syringes (ITU Use Only)
2.5mg in 1mL oral solution (unlicensed)
2mg/ml oral solution (Ozalin®)- additional oral formulation of midazolam pre-medication for anxious children prior to anaesthesia. Decision subject to each Trust carry out their own risk assessment on the use of the product.
Intranasal midazolam 40mg in 1mL and lidocaine 20mg in 1mL (Only for use prior to cannulation for adult patients with special needs receiving dental treatment under IV sedation
MHRA Letters sent to healthcare professionals (January 2018): Buccolam (midazolam) – risk of inhalation / ingestion of tip cap of prefilled plastic syringes.
1mg tablets
MHRA Drug Safety Update (October 2007): Lorazepam: reduction of maximum daily dose.
75mg injection
Injection and suppositories can be used peri-operatively
MHRA Drug safety Update (October 2012): Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks.
MHRA Drug Safety Update (December 2007): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks.
MHRA Guidance (January 2015): Cox-2 selective inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs): Cardiovascular safety.
20mg in 10mL and 150mg in 30mL injection
Reserved for patients at risk of bronchospasm
20mg injection
MHRA Drug Safety Update (July 2014): Intravenous dantrolene: risk of undissolved crystals.